Inside COMBACTE network: global information for a global problem.

Slides:

Advertisements

Similar presentations

THE COMMONWEALTH FUND Source: McCarthy and Leatherman, Performance Snapshots, Catheter-Associated Urinary Tract Infections:

Advertisements

European Centre for Disease Prevention and Control

Prevention of Sepsis Among Neonates Admitted to Intensive Care Units through Promotion of Infection Control Safe Injection Global Network Meeting in Cambodia,

1 Benoît GUERY Infectious Diseases CHRU Lille Antibiotic strategies How to treat Multi-drug-resistant Pseudomonas.

Issues, trends, and resources for combating the problem. Nancy Hudecek RN, BSN, MS Director, Risk Management, Patient Safety, and Quality Improvement Today’s.

Hospital Surveillance. Impact of infectious diseases  IDs are considered to be the leading cause of death  Mass population movement  Emerging and re-emerging.

Nosocomial infection Hospital Infection. Hospital acquired infections Nosocomial infections are those that originate or occur in a hospital or hospital-like.

Point Prevalence Survey of Hospital- Acquired Infections & Antimicrobial Use in Ireland PPS Data Collector Training April 2012 Background & Introduction.

Infection Prevention & Control Neil Wigglesworth Nurse Consultant, Infection Control 23 rd June 2008.

Nosocomial Infections in Rural Hospitals William R. Barnett Robert Bolger MEDT 401 – Issues in Health Care April 29, 2004.

The epidemiology of HAI Scotland Dr Jacqui Reilly Consultant Epidemiologist Head of HAI and IC Group.

Part I BACKGROUND VENTILATOR ASSOCIATED PNEUMONIA.

© Aurora Health Care, Inc. Carbapenem Resistant Enterobacteriaceae The Alphabet Soup of Infection Prevention Aurora Health Care System Infection Prevention.

Division of Public Health CRE Surveillance and Prevention of Transmission in Healthcare Settings Gwen Borlaug, CIC, MPH Coordinator, Healthcare-Associated.

Antimicrobial Resistance patterns among nosocomial gram negative bacilli by E-test and disc diffusion methods in Sina and Imam Hospital.

Microbes and Multicellularity: The Biofilm Concept

MICROBIOLOGICAL EPIDEMIOLOGY OF RESPIRATORY SPECIMENS IN ICU PATIENTS Dr Farooq Cheema, Dr Waseem Tariq, Dr Raja Ishtiaq, Dr Tabassum Qureshi, Dr Vincent.

REtrospective observational Study to assess the clinical management and outcomes of hospitalised patients with Complicated Urinary tract INfection in countries.

Epidemiology of Hospital Acquired Infections By Alena Bosconi, Candice Smith, Dusica Goralewski SUNY Delhi Biol , Infection and Disease Dr. Marsha.

Tigecycline use in serious nosocomial infections: a drug use evaluation Matteo Bassetti*, Laura Nicolini, Ernestina Repetto, Elda Righi, Valerio Del Bono,

Multi-Resistant Gram Negative Microorganisms St Elisabeth Hospital Curacao.

Healthcare-Associated Infection (HAI) and the Role of Diagnostic Testing 1 Date, time, presenter etc. goes here For external use © 2014 Alere. All rights.

Yousef I. Aljeesh, PhD, RN Said Abusalem, PhD, RN Naeem Alkariri, MSN, RN John A. Myers, PhD, MSPH Fawwaz Alaloul, PhD, RN Staff Developed IP Program Increases.

Time for first antibiotic dose is not predictive for the early clinical failure of moderate–severe community-acquired pneumonia Eur J Clin Microbial Infect.

The Incidence of Early Surgical Site Infections in patients undergoing Open Reduction Internal Fixation of femur shaft fractures in KNH Dr Awadh Hemed,

Northern Dimension Antibiotic Resistance Study NoDARS Prof Jaana Vuopio, M.D., Ph.D., PAC 11 side-event, 19 November 2015, Berlin, Germany.

Nosocomial Antibiotic Resistant Organisms

ECDC Point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals Forms V4.2.

AMR containment in Thailand

Christopher A. Guidry MD MS, Robert G. Sawyer MD

PPS Data Collector Training April 2017

Surgical site infections – do we have a problem?

Nitroxoline does not result in microbiological eradication in geriatric patients with lower urinary tract infection: a prospective cohort study C. Forstner1,2*,,

Etiology of bacteremia in children under 5 years in Southern Mali

Are the neurological rehabilitation wards at higher risk for multi-drug resistant micro-organisms infections? A retrospective analysis from a rehabilitation.

SEPSIS COLLABORATIVE Clinical Measures Scorecard Classification

Florida’s Hospitals: Five Years of Improved Quality

The Duration of Hypotension Prior to Initiation of Effective Antimicrobial Therapy is the Critical Determinant of Survival in Human Septic Shock Anand.

Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted.

Background Goals Methods Conclusions Results

TYPES OF NOSOCOMIAL INFECTIONS

Hospital acquired infections

Introduction Materials and methods Results Conclusions

Perspectives in Surgical Infections

Networks of hospitals: building a common strategy for HAI prevention and control and antimicrobial policy Tomasz Ozorowski, M.D. University of Medical.

ECDC-EMEA Joint Technical Report Part I: Trends and burden of antimicrobial resistance in the European Union Zsuzsanna Jakab, Director European Centre.

Prevention: The Answer for Bacterial Resistance

GLOBAL POINT PREVALENCE SURVEY

Risk factors for carbapenem-resistant Enterobacteriaceae (CRE) carriage at the time of hospital admission Siddharth Mookerjee,1 Eleonora Dyakova,1 Frances.

Thirty-day mortality of nosocomial systemic bacterial infections according to antibiotic susceptibility in an 800-bed teaching hospital in France D.

C. Hauck, E. Cober, S. S. Richter, F. Perez, R. A. Salata, R. C

Ms. SHINY THOMAS STAFF NURSE NEUROSURGERY ICU JPNATC, AIIMS New Delhi

GLOBAL POINT PREVALENCE SURVEY OF ANTIMICROBIAL CONSUMPTION AND RESISTANCE (GLOBAL-PPS): RESULTS OF ANTIMICROBIAL PRESCRIBING IN INDIA Dr. Sanjeev K Singh.

Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre.

MRSA=Methicillin resistant Staphylococcus aureus

Single-dose antibiotic prophylaxis for urinary catheter removal does not reduce the risk of urinary tract infection in surgical patients: a randomized.

R. Cantón, M. Akóva, Y. Carmeli, C. G. Giske, Y. Glupczynski, M

G. Höffken Clinical Microbiology and Infection

Optimizing Outcomes in Sepsis Dr. Anand Kumar

Microbiological and epidemiological studies of Enterococcus faecium resistant to amoxycillin in a university hospital in eastern France M. Thouverez,

Combating the spread of carbapenemases in Enterobacteriaceae: a battle that infection prevention should not lose P. Savard, T.M. Perl Clinical Microbiology.

Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle- and high-income countries British Journal of Anaesthesia

W. -L. Yu, M. -F. Lee, H. -J. Tang, M. -C. Chang, J

Prevalence of colonisation with third-generation cephalosporin-resistant Enterobacteriaceae in ICU patients of Heidelberg University Hospitals H. von.

Ventilator Associated Pneumonia

Correlation between time to positivity of blood cultures with clinical presentation and outcomes in patients with Klebsiella pneumoniae bacteraemia: prospective.

Management of nosocomial pneumonia on a medical ward: a comparative study of outcomes and costs of invasive procedures B. Herer, C. Fuhrman, Z. Gazevic,

Overuse/Misuse of Surgical Antimicrobial Prophylaxis (SAP) in a Rural Hospital in Uganda Hiroki Saito, MD MPH;1 Kyoko Inoue, MPH;2 James Ditai, MPH;3.

J. Segreti Clinical Microbiology and Infection

Fighting MDR G-Negative Infections

Presentation transcript:

Inside COMBACTE network: global information for a global problem. EURECA - Substudy of infections due to carbapenem-resistant Enterobacteriacea (CRE) along Europe. Inside COMBACTE network: global information for a global problem. María Paniagua 22 & 23 October 2018 • IMI Scientific Symposium • Brussels, Belgium

INTRODUCTION. BACKGROUND 2009 2013 2015 2016 Klebsiella pneumoniae CR EURECA STUDY EUropean prospective cohort study on Enterobacteriaceae Showing REsistance to CArbapenems 10 countries 50 sites More than 200 investigators More than 2,000 patients Academic Industry Biotech Public-Private Partnership

DESIGN. OBJETIVES INTERIM ANALYSIS 276 CRE cases 115 cUTI 65 IAI 28 PN 38 BSI DESIGN. OBJETIVES TARGETED CRE INFECTIONS Complicated urinary tract infection (cUTI) Intra-abdominal (IAI) Pneumonia (PN) Bacteremia (BSI)

EURECA. Substudy 1. CRE prospective cohort. Interim Analysis Main Results EPIDEMIOLOGY All 276 n (%) cUTI 115 IAI 65 PN 28 BSI 68 Healthcare associated Nosocomial 61 (22) 198 (72) 39 (34) 65 (56) 7 (11) 56 (86) 6 (22) 18 (64) 9 (13) 59 (87) Medical Service Surgical ICU 134 (48) 74 (27) 66 (24) 76 (66) 28 (24) 10 (9) 21 (32) 33 (51) 11 (17) 13 (46) 3 (11) 12 (43) 24 (35) 10 (15) 33 (49) Nosocomial/Healthcare-associated infections Presence in all services (Source-related) RISK FACTORS All 276 n (%) cUTI 115 IAI 65 PN 28 BSI 68 Antibiotics use (3mo) 234 (85) 95 (84) 57 (88) 25 (89) 57 (84) Another CRE at same ward 89 (37) 24 (21) 29 (44) 6 (24) 30 (44) Previous Hospitalisation (6mo) 172 (62) 77 (67) 44 (68) 16 (57) 35 (52) Central line (3mo) 133 (48) 35 (30) 35 (54) 13 (46) 50 (74) Urinary catheter (3mo) 202 (73) 95 (83) 37 (57) 18 (64) 52 (77) Mechanic Ventilation (3mo) 88 (32) 12 (10) 25 (39) 12 (43) 39 (57) Surgery last month 89 (32) 22 (19) 34 (52) 9 (32) 24 (35) Prev. CRE colonization/infection 69 (25) 26 (23) 19 (29) 15 (22) High rates of previous ATBs use (85%) High rates of CRE patients in the same ward High rates of previous hospitalisation High rates of previous “hospital procedures” (Source-related) Considerable rates of previous CRE colonization/infection OUTCOMES All 276 n (%) cUTI 115 IAI 65 PN 28 BSI 68 Clinical cure (day 21) 120 (44) 60 (52) 31 (50) 4 (14) 25 (37) Microbiological cure (day 21) 133 (48) 71 (70) 44 (68) 18 (64) 39 (47) All cause mortality (day 30) 57 (21) 19 (17) 6 (9) 3 (11) 29 (42) Related mortality (day 30) 25 (10) 8 (17) 5 (8) 1 (4) 22 (32) Length of hospital stay (med (IQR) 20 (13-25) 19 (14-23) 23 (16-29) 32 (17-30) 16 (10-24) Low rates of Clinical Cure at day 21 (<50%) Acceptable Microbiological Cure at day 21 (50-70%) Variable mortality (Source-related) Long hospital stay associated

CONCLUSIONS EURECA STUDY GLOBAL PROBLEMS  GLOBAL APPROACH  GLOBAL SOLUTIONS PUBLIC-PRIVATE  COLLABORATION  TEAMWORK Multinational and multihospital level of information is crucial in Antimicrobial Resistance, given the importance of providing global and confident information EURECA STUDY Adequate recruitment Results from interim analysis suggest we will answer the objectives.